AMENDMENTS TO THE CLAIMS

Please amend this application as described in the Listing of Claims, which will replace all prior versions and listings of claims in the above-referenced application.

LISTING OF CLAIMS

1-2. (Cancelled).

3. (Withdrawn) A method for intranasal administration of calcitonin which comprises administering intranasally to an individual a solution of calcitonin consisting essentially of calcitonin, chlorobutanol at a concentration of 0.25% weight/weight, and water and having a pH of about 3.5, sodium chloride at a concentration of about 0.85%, and optionally hydrochloric acid in an amount sufficient to adjust the pH of the solution to about 3.5, and wherein the aqueous solution has an oxygen at a content of less than about 5%.

4. (Withdrawn) The method of claim 3 wherein the calcitonin is present in solution at a concentration of about 0.0355 weight/weight.

5. (Withdrawn) The method of claim 3 wherein the calcitonin formulation is administered into a nose of an individual through an actuator tip as a spray, wherein the spray has a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

6. (Withdrawn) The method of claim 5 wherein the spray produces droplets, wherein less that 5% of the droplets are less than 10 microns in size.

7. (Withdrawn) The method of claim 5 wherein the spray has a spray pattern major axis of about 31.2 mm and a minor axis of about 27.4 mm.

8. (New) A composition comprising:
an aqueous solution of calcitonin at a concentration of about 0.0355% weight/weight;
chlorobutanol at a concentration of about 0.25% weight/weight;
sodium chloride at a concentration of about 0.85% weight/weight; and

hydrochloric acid in an amount sufficient to adjust the pH of the solution to about 3.5;
wherein the composition is suitable for intranasal administration in humans.

9. (New) The composition of claim 8, the composition further comprising an aerosol spray through an actuator tip, the spray having a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

10. (New) The composition of claim 8, the composition further comprising an aerosol spray through an actuator tip, the spray having a spray pattern major axis of about 31.2 mm and a minor axis of about 27.4 mm.

11. (New) The composition of claim 8, the composition further comprising an aerosol spray through an actuator tip, the spray comprising droplets wherein less that 5% of the droplets are less than 10 microns in size.

12. (New) A composition comprising:
an aqueous solution of calcitonin salmon at a concentration of 2200 International Units (I.U.) per ml;
chlorobutanol at a concentration of 0.25% weight/weight;
sodium chloride at a concentration of 0.85% weight/weight; and
hydrochloric acid in an amount sufficient to adjust the pH of the solution to 3.5;
wherein the composition is suitable for intranasal administration in humans.

13. (New) The composition of claim 12, the composition further comprising an aerosol spray through an actuator tip, the spray having a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

14. (New) The composition of claim 12, the composition further comprising an aerosol spray through an actuator tip, the spray having a spray pattern major axis of about 31.2 mm and a minor axis of about 27.4 mm.

15. (New) The composition of claim 12, the composition further comprising an aerosol spray through an actuator tip, the spray comprising droplets wherein less that 5% of the droplets are less than 10 microns in size.

16. (New) A pharmaceutical composition comprising:
an aqueous solution of calcitonin salmon at a concentration of 2200 International Units (I.U.) per ml;
chlorobutanol at a concentration of 0.25% weight/weight;
sodium chloride at a concentration of 0.85% weight/weight; and
hydrochloric acid in an amount sufficient to adjust the pH of the solution to 3.5;
wherein the composition is suitable for intranasal administration in humans.

17. (New) The composition of claim 16, the composition further comprising an aerosol spray through an actuator tip, the spray having a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

18. (New) The composition of claim 16, the composition further comprising an aerosol spray through an actuator tip, the spray having a spray pattern major axis of about 31.2 mm and a minor axis of about 27.4 mm.

19. (New) The composition of claim 16, the composition further comprising an aerosol spray through an actuator tip, the spray comprising droplets wherein less that 5% of the droplets are less than 10 microns in size.